Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $19.88

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Hold” by the twelve analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $19.8750.

Several equities analysts recently issued reports on the stock. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Monday, March 23rd. They set a “neutral” rating on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Finally, Rodman & Renshaw assumed coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They set a “buy” rating and a $17.00 price objective on the stock.

Jasper Therapeutics Stock Down 2.6%

NASDAQ:JSPR opened at $0.88 on Friday. The firm’s fifty day simple moving average is $1.32 and its 200 day simple moving average is $1.76. The stock has a market cap of $24.52 million, a P/E ratio of -0.19 and a beta of 3.08. Jasper Therapeutics has a twelve month low of $0.81 and a twelve month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.47. On average, analysts expect that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds have recently made changes to their positions in the company. Simplify Asset Management Inc. bought a new position in Jasper Therapeutics in the third quarter worth $1,450,000. Propel Bio Management LLC purchased a new position in Jasper Therapeutics during the third quarter valued at $2,449,000. Kingdon Capital Management L.L.C. boosted its holdings in shares of Jasper Therapeutics by 93.5% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,324,845 shares of the company’s stock valued at $3,153,000 after buying an additional 640,138 shares in the last quarter. Knott David M Jr bought a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at $408,000. Finally, Squarepoint Ops LLC grew its position in shares of Jasper Therapeutics by 1,919.5% in the 4th quarter. Squarepoint Ops LLC now owns 281,926 shares of the company’s stock worth $516,000 after buying an additional 267,966 shares during the period. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.